Labrycor

Isoprenaline Hydrochloride, the active ingredient in Labrycor, is a beta‑adrenergic agonist (non‑selective) presented as an injection solution for intravenous use. It treats bradycardia, heart block, and cardiac arrest in acute care settings.

GNH USA supplies Labrycor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Originating from the European Union market, the product meets EU quality standards. The supply chain adheres to stringent regulatory requirements ensuring product integrity.

Isoprenaline Hydrochloride is used in cardiovascular emergencies to increase heart rate and improve conduction.

- Bradycardia: restores adequate heart rate in patients with symptomatic slow heart rhythm. - Heart block: improves atrioventricular conduction in second‑degree or higher block. - Cardiac arrest: provides temporary cardiac stimulation during resuscitation efforts.

Isoprenaline Hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Tachycardia: excessive increase in heart rate. - Hypertension: elevated blood pressure. - Headache: mild to moderate intensity. - Tremor: fine shaking of hands or limbs. - Nausea: gastrointestinal discomfort. - Palpitations: awareness of rapid heartbeat.

Serious or Rare Side Effects: - Myocardial ischemia: reduced blood flow to heart muscle. - Severe hypotension: dangerous drop in blood pressure. - Pulmonary edema: fluid accumulation in lungs. - Anaphylactic reaction: life‑threatening allergy. - Ventricular fibrillation: life‑threatening arrhythmia.

When using Isoprenaline Hydrochloride, careful monitoring and specific precautions are essential to ensure patient safety.

- Cardiac monitoring: continuous ECG and blood pressure monitoring during infusion. - Dose titration: adjust infusion rate based on clinical response and hemodynamic parameters. - Contraindications: avoid in patients with pheochromocytoma or severe tachyarrhythmias. - Caution in ischemic heart disease: use only under strict supervision due to risk of myocardial ischemia. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Isoprenaline Hydrochloride can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Beta‑blockers: antagonize therapeutic effect. - Calcium channel blockers: may exacerbate hypotension. - MAO inhibitors: increase risk of severe hypertension. - Tricyclic antidepressants: potentiate arrhythmic risk.

Moderate Interactions (Monitor Closely): - Diuretics: may amplify electrolyte disturbances. - Digoxin: heightened risk of arrhythmias. - ACE inhibitors: additive blood pressure lowering. - General anesthetics: possible synergistic cardiovascular depression. - Antihypertensives: may require dose adjustments.